Analytical Data
-
Gene name
CHRNb4
- Application
-
Alternative Names
CHRNb4；Neuronal acetylcholine receptor subunit beta-4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30926
-
Expression Region
1-498aa
-
AA Sequence
MRRAPSLVLFFLVALCGRGNCRVANAEEKLMDDLLNKTRYNNLIRPATSSSQLISIKLQLSLAQLISVNEREQIMTTNVWLKQEWTDYRLTWNSSRYEGVNILRIPAKRIWLPDIVLYNNADGTYEVSVYTNLIVRSNGSVLWLPPAIYKSACKIEVKYFPFDQQNCTLKFRSWTYDHTEIDMVLMTPTASMDDFTPSGEWDIVALPGRRTVNPQDPSYVDVTYDFIIKRKPLFYTINLIIPCVLTTLLAILVFYLPSDCGEKMTLCISVLLALTFFLLLISKIVPPTSLDVPLIGKYLMFTMVLVTFSIVTSVCVLNVHHRSPSTHTMAPWVKRCFLHKLPTFLFMKRPGPDSSPARAFPPSKSCVTKPEATATSTSPSNFYGNSMYFVNPASAASKSPAGSTPVAIPRDFWLRSSGRFRQDVQEALEGVSFIAQHMKNDDEDQSVVEDWKYVAMVVDRLFLWVFMFVCVLGTVGLFLPPLFQTHAASEGPYAAQRD
-
Molecular Weight
56.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The CHRnB4 protein, a subtype of nicotinic acetylcholine receptors (nAChRs), has garnered significant interest in neuroscientific research due to its critical role in modulating neurotransmission in the central and peripheral nervous systems. This receptor subtype is predominantly expressed in the brain, where it influences various cognitive functions, including learning, memory, and attention. Furthermore, CHRnB4 has been implicated in a range of neurological disorders, such as Alzheimer's disease, schizophrenia, and nicotine addiction. Researchers are investigating the structure and functional dynamics of recombinant CHRnB4 proteins to better understand their molecular mechanisms and potential therapeutic targets. Advanced techniques, including X-ray crystallography and electrophysiological assays, are employed to characterize the receptor’s binding sites and activation pathways. By elucidating the pharmacological properties of CHRnB4, scientists aim to develop novel compounds that can selectively modulate its activity, thus paving the way for innovative treatments for diseases associated with cholinergic dysfunction. As the understanding of CHRnB4 continues to evolve, its potential as a biomarker for neurological conditions and a target for drug discovery remains an area of active exploration.
